Company: TLSA
Filing Date: 2025-03-24
Form Type: F-3
Source: 0001013762-25-001691
Chunk: 47

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-03-24
Form: F-3
Chunk 47
---
 candidates and could materially adversely affect 
 our research and development efforts and business, financial condition and results of operations.                                    |

| ● | We have incurred net losses                                                                                                             
 in every year since our inception. We anticipate that we will continue to incur losses for the foreseeable future and may never achieve 
 or maintain profitability.                                                                                                              |

| ● | We need substantial additional                                                                                                      
 funding to complete the development of our product candidates, which may not be available on acceptable terms, if at all. Failure   
 to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development, research 
 operations or future commercialization efforts, if any.                                                                             |

| ● | We rely, and expect to                                                                                                                   
 continue to rely, on third parties to conduct our preclinical studies and clinical trials and for product manufacturing. If these        
 third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory 
 approval for or commercialize our product candidates.                                                                                    |

| ● | Our rights to develop and                                                                                                              
 commercialize our product candidates are subject to the terms and conditions of licenses granted to us by others. If we fail to comply 
 with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights 
 that are important to the business.                                                                                                    |

| ● | If our competitors are                                                                                                                      
 able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as our product candidates, 
 we may not be able to have competing products approved by applicable regulatory authorities for a significant period of time. In            
 addition, even if we obtain orphan drug exclusivity for any of our products, such exclusivity may not protect us from competition.          |

| ● | Healthcare legislative                                                                
 reform measures may have a negative impact on our business and results of operations. |

| ● | Our common shares may be                                                                       
 delisted from The Nasdaq Capital Market if we fail to comply with continued listing standards. |

| ● | Because we are a foreign                                                              
 corporation, you may not have the same rights as a shareholder in a U.S. corporation. |

| ● | Claims of U.S. civil liabilities   
 may not be enforceable against us. |

| ● | If                                                                                          
 we are a passive foreign investment company, there could be adverse U.S. federal income tax 
 consequences to U.S. holders.                                                               |

Corporate Information We were originally incorporated under the laws of England and